Genéricos/Investigación

El mercado de los medicamentos genéricos en Brasil

Genéricos/Investigación | Posted 16/07/2021

El mercado farmaceútico brasileño ha experimentado muchos cambios desde que se introdujeron las leyes sobre medicamentos genéricos. 

Leyes sobre el envasado, sustitución y prescripción de medicamentos genéricos en Brasil

Genéricos/Investigación | Posted 09/07/2021

Según la Agencia Nacional de Vigilancia Sanitaria (Agencia Nacional de Vigilancia Sanitaria, ANVISA), la aprobación de medicamentos tiene como objetivo mejorar el acceso de la población brasileña a medicamentos mejores, seguros y de calidad a precios más bajos.

Requisitos legales sobre estudios de equivalencia para medicamentos genéricos en Brasil

Genéricos/Investigación | Posted 02/07/2021

La creación del sistema legal para medicamentos genéricos comenzó con la introducción de la Ley Número 9787 en febrero de 1999 (Brasil 1999). Según la Agencia Nacional de Vigilancia Sanitaria (ANVISA), la aprobación de medicamentos tiene por fin el mejorar el acceso de la población brasileña a mejores medicamentos seguros y de calidad a menor precio. 

‘Backlog’ de patentes de medicamentos en Brasil

Genéricos/Investigación | Posted 25/06/2021

En un artículo sobre ‘How much does the backlog on drug patents cost for health in Brazil?’, Januzzi el al. en 2017 [1] mostraron atrasos en el análisis de solicitudes de patentes en Brasil. Estos atrasos, conocidos como ‘backlogs‘, extienden el plazo de las patentes otorgadas a medicamentos y retrasan la entrada de genéricos en el mercado.

Non-profit generics manufacturers in the US reduce foreign dependence

Genéricos/Investigación | Posted 11/06/2021

Non-profit generics drug manufacturers have the potential to make important contributions to reduce foreign dependence on generic drugs in the US, argues an article published in The Journal of Law Medicine and Ethics [1].

More out-of-pocket costs for US patients with rising prescription drug prices

Genéricos/Investigación | Posted 31/05/2021

Increasing prices of brand-name drugs in the US, leaves patients with increasing costs at the pharmacy, says a study published in JAMA Network Open [1]. 

Difficult-to-make drugs meet US quality standards

Genéricos/Investigación | Posted 14/05/2021

Difficult-to-make prescription pharmaceuticals marketed in the US consistently meet quality standards even when manufactured outside the country, finds a study published in JAMA Network Open [1].

New in vitro–in vivo simulations predict generic bioequivalence

Genéricos/Investigación | Posted 07/05/2021

If we can predict the outcome of bioequivalence studies in the generic drug development process, we can save time and money. Now, a new in vitro–in vivo simulation (IVIVS) approach to predict the in vivo outcome of these studies, published in Materials [1], has been developed by researchers National and Kapodistrian University of Athens.

Dispensing branded drugs costs Medicare over a billion dollars

Genéricos/Investigación | Posted 09/04/2021

Branded drugs dispensed instead of generics at the request of physicians and patients have incurred annual costs of over US$1 billion to the Medicare programme. and US$270 million to patients, reveals a study published in JAMA Network Open [1]. 

Technological approaches to drug repurposing for cancer treatment

Genéricos/Investigación | Posted 02/04/2021

Cancer is one of the leading causes of death in the world today, causing nearly 10 million deaths in 2018 alone. Despite extensive research into new treatments, when these eventually reach the market, they are often very expensive. The strategy of drug repurposing is being applied to identify already approved drug products as potential cancer therapies. This can bring new cancer treatments to patients faster and at a lower price. A review, published in Signal Transduction and Targeted Therapy [1], summarizes approaches used for drug repurposing and discusses the main barriers to uptake.